FDA approves Sandoz’s natalizumab biosimilar, likely putting a damper on Biogen’s Tysabri sales

On the back of Sandoz’s FDA approval for the first-ever natalizumab biosimilar, branded as Tyruko, Biogen now has a formidable multiple sclerosis market competitor for its top-selling monoclonal antibody Tysabri.

Keren Haruvi

“Tyruko has the potential to extend the reach of natalizumab treatment for these…
Click here to view original post